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ABSTRACT
Introduction: KRAS oncogene mutations (MUTKRAS) drive resistance to EGFR 
inhibition by providing alternative signaling as demonstrated in colo-rectal cancer. In 
non-small cell lung cancer (NSCLC), the efficacy of treatment with EGFR tyrosine kinase 
inhibitors (EGFR-TKIs) depends on activating EGFR mutations (MUTEGFR). However, 
inhibition of EGFR may select resistant cells displaying alternative signaling, i.e., 
KRAS, or restoration of EGFR activity due to additional MUTEGFR, i.e., the c.2369C > T 
(p.T790MEGFR).
Aim: The aim of this study was to investigate the appearance of MUTKRAS during 
EGFR-TKI treatment and their contribution to drug resistance.
Methods: This study used cell-free circulating tumor DNA (cftDNA) to evaluate 
the appearance of codon 12 MUTKRAS and p.T790MEGFR mutations in 33 advanced NSCLC 
patients progressing after an EGFR-TKI. 
Results: p.T790MEGFR was detected in 11 (33.3%) patients, MUTKRAS at codon 12 
in 3 (9.1%) while both p.T790MEGFR and MUTKRAS codon 12 were found in 13 (39.4%) 
patients. Six patients (18.2%) were KRAS wild-type (WTKRAS) and negative for 
p.T790MEGFR. In 8 subjects paired tumor re-biopsy/plasma samples were available; 
the percent concordance of tissue/plasma was 62.5% for p.T790MEGFR and 37.5% for 
MUTKRAS. The analysis of time to progression (TTP) and overall survival (OS) in WTKRAS 
vs. MUTKRAS were not statistically different, even if there was a better survival with 
WTKRAS vs. MUTKRAS, i.e., TTP 14.4 vs. 11.4 months (p = 0.97) and OS 40.2 vs. 35.0 
months (p = 0.56), respectively. 
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INTRODUCTION
Activating mutations of epidermal growth factor 
receptor (MUTEGFR) predict sensitivity to tyrosine kinase 
inhibitors (TKI) in non-small cell lung cancer (NSCLC). 
Despite a very high response rate (about 70%) to first-
line treatment with the EGFR-TKIs (erlotinib, gefitinib or 
afatinib) in MUTEGFR NSCLC, tumors invariably progress 
after a median of 9–13 months from the beginning of 
treatment [1–3]. 
The understanding of the molecular basis of acquired 
resistance to TKI [4] and its application to treatment 
monitoring may improve treatment management by 
discontinuing ineffective treatments and directing 
towards most appropriate second line options before 
clinical progression may occur. Indeed, EGFR signaling is 
maintained in most cases that develop secondary resistance 
[5] suggesting that additional molecular mechanisms can 
bypass EGFR-TKI inhibition reactivating the signaling 
pathway. Several mechanisms of acquired resistance 
to EGFR-TKI have been described after progression, 
including c.2369C > T (p.T790M) EGFR gatekeeper 
mutation (p.T790MEGFR, ~50% of patients) [6], MET 
(5–15%) [7] or HER2 (12%) [8] amplifications, PIK3CA 
(4.1%) [9] or BRAF (1%) [10] mutations or transformation 
into small cell histology (3%) [11]. 
NSCLC heterogeneity can drive the therapeutic 
decisions [12]; therefore, tissue availability is increasingly 
recognized as a crucial issue. Unfortunately, the location 
of the tumor and the risk of complications are serious 
limitations to re-biopsies in NSCLC [13]. Alternatively, 
the detection of somatic mutations in cell-free tumor DNA 
(cftDNA) released in plasma could be instrumental for a 
better understanding of the genetic modifications driven 
by the selective pressure of drug treatments [14]. 
Interestingly, approximately 15–25% of patients 
with NSCLC have KRAS mutations (MUTKRAS), resulting 
in constitutive activation of KRAS signaling pathways. 
MUTKRAS is a negative predictor of benefit to anti-EGFR 
antibodies in colo-rectal cancer, while it seems to be a 
negative predictor of response to EGFR-TKIs in EGFR 
wild type (WTEGFR) NSCLC patients [15]. In a previous 
study on a large collection of NSCLC tissues from patients 
with acquired resistance to EGFR-TKI, NRAS or KRAS 
mutations were not demonstrated [10]. Despite these 
negative results, we employed a sensitive ddPCR-based 
platform to investigate the presence of MUTKRAS alleles 
in plasma of patients resistant to EGFR-TKIs and we 
were able to demonstrate a potential role of MUTKRAS in 
acquired resistance to EGFR-TKI, besides the p.T790MEGFR. 
This finding reveals a potential new mechanism of 
resistance to EGFR-TKI and underscores the need of 
a periodic monitoring of somatic mutations of known 
oncogenes to deliver the best personalized treatment in a 
timely fashion.
RESULTS
The clinical characteristics of patients are reported 
in Table 1. Of 33 patients, 20 (60.6%) were female and 13 
(39.4%) male. Median age was 62 years (range 41 – 75); 
32 patients were affected by a stage IV disease, while one 
was a stage IIIB NSCLC. The frequency of activating 
MUTEGFR was as follows: 20 patients (60.6%) showed 
ex19delEGFR, 10 patients (30.3%) p.L858REGFR, 2 patients 
(6.1%) p.L747PEGFR and 1 patient presented ex19insEGFR 
(3%). As expected, the majority of them (66.7%) was 
never-smokers, while 9 (27.2%) and 2 (6.1%) patients 
were former- and current-smokers, respectively. Twenty-
seven (81.8%) subjects received gefitinib and 6 (18.2%) 
erlotinib; the treatment was administered as first-line in 
23 (69.7%) (including 2 as maintenance), second-line in 
6 (18.2%) and third or further lines in 4 patients (12.1%). 
The majority of them (66.7%) presented partial response 
to TKI treatment and only 1 patient showed complete 
response (Table 1). Stable and progressive diseases were 
observed in 4 (12.1%) and 6 subjects (18.2%), respectively. 
Patients who have progressed on EGFR-TKI treatment, 
all receiving gefitinib, presented the following molecular 
profile in their primary tumors: p.L747PEGFR and ex19delEGFR 
(n = 1 each) and p.L858REGFR (n = 4). Median time to 
progression (TTP) was 13.6 months (95% Confidence 
Interval, CI, range 8.0 – 19.2 months) and median overall 
survival (OS) was 40.2 months (95% CI range 25.8–54.7 
months) for the overall population.
The description of patients with activating MUTEGFR 
in their primary tumors as well as the percentages of 
p.T790MEGFR and MUTKRAS alleles in cftDNA at the time 
of EGFR-TKI progression is reported in Table 2. In 16 
patients (48.5%), a codon 12 MUTKRAS was detected in 
cftDNA (Figure 1). In addition to this, the p.T790MEGFR 
(c.2369C > T) second site mutation was present in the 
cftDNA of 24 patients (72.7%). Interestingly, 13 patients 
(39.4%) had both the MUTKRAS and p.T790MEGFR, while 3 
(9.1%) and 11 (33.3%) subjects displayed only MUTKRAS 
or p.T790MEGFR, respectively (Figure 1). Six subjects 
displayed no mutations. 
The association between smoking habit and the 
occurrence of MUTKRAS in cftDNA was investigated. 
Regarding the 11 patients with smoking history, 2 (18.2%) 
Conclusions: MUTKRAS could be an additional mechanism of escape from EGFR-TKI 
inhibition and cftDNA is a feasible approach to monitor the molecular development 
of drug resistance.
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presented MUTKRAS and 9 (81.8%) were wild-type 
(WTKRAS). On the contrary, of 22 non-smoking subjects, 
14 (63.3%) were MUTKRAS and 8 (36.4%) WTKRAS. 
Fisher’s extact test revealed that non-smoking habit and 
MUTKRAS were significantly associated (p = 0.026).
In 8 patients, paired re-biopsies and cftDNA were 
available. The 8 re-biopsies were performed in a different 
tumor site with respect to the initial diagnosis, the choice 
being dependent on several factors, i.e., anatomical 
accessibility, new or progressing lesions. The analysis of 
re-biopsies by standard methods and ddPCR demonstrated 
p.T790MEGFR in 4 (standard) vs. 2 (ddPCR) samples and 
MUTKRAS in none (standard) vs. 3 (ddPCR) specimens. 
p.T790MEGFR and MUTKRAS were detected in 7 and 5 
cftDNA specimens, respectively. 
The analysis of KRAS status by ddPCR in the 
biopsies at diagnosis revealed the presence of MUTKRAS 
in 2 patients, who were WTKRAS by standard method. 
Therefore, the percentage of patients developing 
MUTKRAS as a mechanism of acquired resistance is 42% 
(14 patients). In terms of TTP and OS, there was no 
difference between these patients and the others (p = 0.19 and 
p = 0.13, respectively). 
The concordance between tissue of re-biopsies 
(standard methods) and plasma (ddPCR), calculated by 
combining positive and negative results, was 62.5% and 
37.5% for p.T790MEGFR and MUTKRAS, respectively (Table 3). 
Moreover, three paired samples found positive for the 
p.T790MEGFR on re-biopsies (standard methods) and on 
cftDNA (ddPCR), were negative by ddPCR on primary 
tissue (Table 3).
The analysis of survival data stratified according to 
KRAS status in cftDNA, showed that TTP and OS  were 
not statistically different, despite a trend towards a better 
survival in WTKRAS vs. MUTKRAS patients, i.e., TTP 14.4 
vs. 11.4 months (p = 0.97) and OS 40.2 vs. 35.0 months 
(p = 0.56), respectively.
Finally, samples were analysed also for codons 
13 (p.G13D) and 61 MUTKRAS and MUTNRAS, and 
V600EBRAF and all the samples were found to be wild-type. 
Unfortunately, due to sample restriction, cftDNA was 
insufficient to perform the analysis of PI3K/Akt mutations.
Table 1: Characteristics of patients
No. (%)
Age years (range) 62 (41 – 75)
Gender
male 13 (39.4%)
female 20 (60.6%)
Smoking habit
smokers 2 (6.1%)
never-smokers 22 (66.7%)
former-smokers 9 (27.2%)
Stage
IIIB 1 (3%)
IV 32 (97%)
EGFR activating mutation
ex19del 20 (60.6%)
p.L858R 10 (30.3%)
p.L747P 2 (6.1%)
ex19ins 1 (3%)
Line of treatment 1 23 (69.7%)
2 6 (18.2%)
≥ 3 4 (12.1%)
TKI gefitinib 27 (81.8%)
erlotinib 6 (18.2%)
Response CR 1 (3%)
PR 22 (66.7%)
SD 4 (12.1%)
PD 6 (18.2%)
TTP months (95% CI) 13.6 (8.0 – 19.2)
OS months (95% CI) 40.2 (25.8 – 54.7)
Abbreviations: TKI: tyrosine kinase inhibitor; TTP: time to progression; OS: overall survival
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DISCUSSION
The present study demonstrates the presence of 
MUTKRAS in the cftDNA of a significant proportion of 
patients progressing after EGFR-TKI treatment. In 
addition to this, the present study provides evidence that 
sensitizing MUTEGFR and MUTKRAS can coexist after the 
selective pressure of EGFR-TKI treatment. 
p.T790MEGFR determines acquired resistance by 
increasing the affinity of EGFR to ATP [16, 17]. 
p.T790MEGFR has been described in re-biopsies of 50–63% 
of tumors progressing under EGFR-TKI treatment [4, 11] 
and in the cftDNA at a frequency similar to our study 
[18–0]. Because drugs active on p.T790MEGFR, such as 
AZD9291 and rociletinib [21, 22], are under clinical 
study and will be available soon in the clinical practice, 
the identification of this molecular marker is of utmost 
clinical relevance. 
In our study, p.T790MEGFR was more frequent in 
L858REGFR patients than in ex19delEGFR ones (80% vs. 67%); 
on the contrary, MUTKRAS in cftDNA was detected in 
55% of patients with ex19delEGFR vs. 30% of patients with 
Table 2: Types of activating mutations of MUTEGFR in primary tumor and % of p.T790MEGFR and MUTKRAS 
alleles in cftDNA. “-“ Indicates wild-type allele
Sample Activating MUTEGFR p.T790MEGFR % MUTKRAS %
1 Ex19del 7% 2%
2 p.L858R 11% -
3 Ex19del 1% 1%
4 Ex19del 3% 2%
5 Ex19del - 1%
6 Ex19del - 1.5%
7 Ex19del 1.5% 1%
8 p.L858R 1% -
9 Ex19del - -
10 Ex19del - -
11 p.L858R - -
12 p.L858R 5% -
13 Ex19del - -
14 p.L747P 2% -
15 p.L858R - -
16 Ex19del 1% -
17 Ex19del 1% 2%
18 Ex19del 16% 1%
19 p.L858R 23% 1%
20 Ex19del 96% 98%
21 Ex19del - -
22 Ex19ins - 1%
23 Ex19del 33% 2%
24 p.L747P 1% 1%
25 p.L858R 5% 2%
26 p.L858R 3% 1%
27 Ex19del 9% 3%
28 p.L858R 14% -
29 Ex19del 28% -
30 p.L858R 7% -
31 Ex19del 39% -
32 Ex19del 6% -
33 Ex19del 43% -
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L858REGFR. To our knowledge, a mechanism of resistance 
depending on activating MUTEGFR has not been previously 
reported; however, this cohort is too small to draw any 
conclusion.
MUTEGFR and MUTKRAS are mutually exclusive 
in primary NSCLC and only anecdotal case reports 
described their coexistence [23, 24]. MUTKRAS occurs in 
approximately 20% of NSCLC cases at diagnosis, more 
frequently in Caucasian population, adenocarcinomas, 
males and current smokers [25, 26]. About 90% of KRAS 
mutations occur in exon 2 (codon 12 and 13), while 
exon 3 (codon 61) is less frequently involved [26, 27]; 
in never-smokers with lung adenocarcinoma, MUTKRAS 
is more frequently a transition (G to A) compared to 
transversion in current smokers [25]. Colo-rectal cancer 
cells with MUTKRAS treated with anti-EGFR monoclonal 
antibodies are able to escape growth inhibition by 
several mechanisms, including MUTRAS [28]. While the 
role of MUTKRAS in primary resistance to EGFR-TKIs in 
molecularly unselected NSCLC is quite well established 
[29, 30], its development and role in acquired resistance 
to EGFR-TKIs in MUTEGFR patients has not been explored 
in detail. In a previous work on a large collection of 
NSCLC tissues from patients with acquired EGFR-TKI 
resistance, MUTNRAS or MUTKRAS were not demonstrated 
[10]. However, comparison with the present results 
is not possible because detailed information were not 
provided neither on the timing of sampling with respect 
of development of TKI resistance nor on the type of 
tissue analysed. Therefore, we addressed this issue and 
a sensitive ddPCR-based platform was employed to 
investigate the presence of MUTKRAS alleles besides the 
well-known p.T790MEGFR. Due to its high sensitivity, 
ddPCR is able to identify small amounts of MUTKRAS 
and many methodological issues need to be addressed 
prospectically, particularly the threshold level of both 
MUTKRAS and p.T790MEGFR to be considered clinically 
relevant. However, a mechanism of drug resistance 
does not necessarily reflect biologic aggressiveness and 
the lack of difference in OS between KRAS wild-type 
and mutated patients it is therefore not surprising. The 
numeric dimension of the cell clone bearing MUTKRAS 
should be taken into consideration as well. Nevertheless, 
despite the low proportion of smokers in our cohort, the 
high prevalence of MUTKRAS could support its role of as 
mechanism of acquired resistance.
Eight patients underwent re-biopsy after tumor 
progression during EGFR-TKI, allowing a comparison 
between tissue and cftDNA. The detection of mutations in 
cftDNA but not in re-biopsy, using both standard methods 
and ddPCR, could suggest the presence of heterogeneity 
within metastatic sites or the lower performance of ddPCR 
in the presence of paraffin. Nevertheless, the detection of 
mutations in both plasma and tissue by ddPCR, but not by 
standard methods, could be due to the higher sensitivity of 
ddPCR analysis. Two patients, initially diagnosed WTKRAS 
by standard method, were re-analysed by ddPCR and were 
found MUTKRAS in the primary biopsy, suggesting that the 
MUTKRAS clone co-existed with activating MUTEGFR since 
the beginning, as also demonstrated in previous reports 
[23, 24]. In these patients, MUTKRAS cannot strictly be 
considered a mechanisms of resistance but it could be 
possible that EGFR-TKI treatment may have favored 
the expansion of MUTKRAS-positive clones. However, 
conclusions cannot be drawn as pre-treatment cftDNA was 
not available.
Figure 1: Occurrence of KRAS and p.T790M mutations in cftDNA of NSCLC patients treated with EGFR-TKI
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Our observation is a pivotal evidence of the 
presence of MUTKRAS in cftDNA of tumors with sensitizing 
MUTEGFR resistant to EGFR-TKIs. A small percentage of 
our patients received EGFR-TKI as third line therapy and 
a new biopsy was not repeated at this time. It could be 
possible that MUTKRAS appeared before the initiation of 
TKI as a mechanism of resistance to previuos therapy. 
This hypotesis is weakened by the evidence that patients 
given second or further lines of therapy showed TTP 
and OS similar to patients treated in first line, although 
a mechanism of resistance does not necessarily affect 
survival. The presence of MUTKRAS has been recently 
reported using next generation sequencing analysis of 
tumor re-biopsies after progression under EGFR-TKI 
treatment [31], similarly to colo-rectal cancer treated with 
EGFR antibodies [32, 33]. It remains to be determined if 
the presence of p.T790MEGFR and MUTKRAS coexist in the 
same tumor cell or arise in different subclones. 
Targeting MUTKRAS proteins is still a challenge 
[34, 35]. Theoretically, combined treatment with KRAS 
and EGFR inhibitors can be administered to patients 
to prevent MUTKRAS-dependent resistance or restore 
sensitivity to EGFR-TKIs, as recently demonstrated 
co-targeting EGFR and MEK [36]. To date, p.T790MEGFR 
remains the most important predictor of efficacy of third 
generation EGFR-TKIs. Moreover, it was found that the 
coexistence of both activating MUTEGFR and MUTKRAS was 
not necessarily a negative predictor for EGFR-TKI therapy 
[23]. With these evidences in mind, all patients with 
p.T790MEGFR should receive third generation EGFR-TKI, 
even in the presence of MUTKRAS. Theoretically, it is 
possible that MUTKRAS identify a less responsive subgroup 
of patients but this hypothesis should be validated 
by monitoring patients prospectically during second-
line therapy. Beside p.T790MEGFR and MUTKRAS, other 
mechanisms of acquired resistance not evaluated in our 
study have been described in tumor re-biopsies after 
EGFR-TKI progression, including actionable mutations 
of MET [7], HER2 [8], PIK3CA [9] or transformation into 
small cell histology (3%) [11].
In conclusion, despite the small number of patients 
involved, the retrospective analysis and the low rate of 
re-biopsies, our results confirm the importance of cftDNA 
analysis for the monitoring of secondary mutations 
associated with EGFR-TKI resistance in NSCLC and 
underline the role of a highly sensitive approach, i.e., 
ddPCR, for the detection of low-level mutations. The 
clinical relevance of these findings, expecially for what 
concerns MUTKRAS, needs to be evaluated prospectively. 
These observations open new perspectives in the molecular 
mechanisms of acquired resistance, indicating a possible 
role of MUTKRAS in tumor escape from pharmacologic 
treatment. The effect of MUTKRAS in NSCLC with 
activating MUTEGFR needs to be further elucidated at 
the molecular level and encourages the development of 
inhibitors MUTKRAS for optimal treatment of patients.
MATERIALS AND METHODS
Study population
A total of 33 NSCLC patients with activating MUTEGFR 
(exon 19 deletion [ex19delEGFR], exon 21 c.2573T > G 
[p.L858REGFR] or exon 19 c.2240T > C [p.L747PEGFR]), 
receiving EGFR-TKI (gefitinib or erlotinib) as per approved 
indication were included in this study. The analysis of 
EGFR mutations in primary tumors was performed by 
standard diagnostic procedures in use in each centre 
participating to this study (i.e., EGFR TKI response®, 
Diatech, Jesi, Italy; Therascreen®, Qiagen, Valencia, CA, 
USA). MUTKRAS were not examined at the time of diagnosis 
because mutually exclusive with activating MUTEGFR. 
Plasma and/or re-biopsy samples were taken at the time of 
disease progression. The analysis of MUTKRAS mutations 
and EGFR c.2369C > T (p.T790MEGFR) in plasma was not 
part of standard clinical management and the study was 
Table 3: Molecular analysis of re-biopsies and comparison with cftDNA
Patient n.
Primary tumor Re-biopsy cftDNA
MUTKRAS
std
MUTKRAS
 ddPCR 
p.T790MEGFR
ddPCR
MUTKRAS
ddPCR
p.T790MEGFR 
std
MUTKRAS
std
p.T790MEGFR
ddPCR
MUTKRAS
 ddPCR
2 - NA - - - - Mut -
4 - Mut Mut Mut - - Mut Mut 
5 - Mut - Mut - - - Mut
19 - - - - Mut - Mut Mut
20 - - - - - - Mut Mut
23 - - Mut Mut Mut - Mut Mut
28 - NA - - Mut - Mut -
30 - NA - - Mut - Mut -
Mut: presence; “-“: absence of mutation; NA: sample not available; std: standard sequencing approach.
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submitted and approved by the Ethics Committee of Pisa 
University Hospital and conducted in accordance to the 
principles of the Declaration of Helsinki; all patients gave 
their signed informed consent before blood collection and 
cftDNA analysis. 
Plasma collection and cftDNA extraction
Six ml of blood were collected in EDTA and 
centrifuged at 4°C for 10 min at 3000 rpm within two 
hours after blood drawing. Plasma samples were stored 
at −80°C until analysis. cftDNA was extracted using a 
QIAmp Circulating nucleic acid Kit (Qiagen®, Valencia, 
CA, USA) from 1 to 3 ml of plasma following the 
manufacturer’s protocol and the DNA was eluted in 100 μl 
of buffer.
Analysis of cftDNA
The investigational part of this study included the 
assessment of codons 12, 13 (p.G13D) and 61 MUTKRAS 
and MUTNRAS, p.T790MEGFR, V600EBRAF in cftDNA. Other 
mutations potentially associated with EGFR-TKI resistance 
were not examined because of the limited amount of 
cftDNA available. The analysis of cftDNA was performed 
by digital droplet PCR (ddPCR, BioRad®, Hercules, 
CA, USA) and ddPCR Mutation Assay (BioRad®). The 
analytic procedure was unable to discriminate the nature 
of the MUTKRAS because the analysis was performed with a 
ddPCR KRAS Multiplex assay.
PCR reactions were assembled into individual wells 
of a single-use injection molded cartridge, according to 
the following protocol: 20 ng of template DNA (4 μl), 
1 μl of 20X target primer/probe assay (FAM), 1 μl of 20X 
wild type primer/probe assay (HEX), 10 μl of 2X ddPCR 
Super Mix and 4 μl of DNAse/RNAse-free water up to a 
total volume of 20 μl. Droplet generation oil (70 μl) was 
then loaded and the cartridge was placed into the droplet 
generator. Using vacuum, sample and oil were mixed, 
generating mono-disperse droplets. Thereafter, 40 μl of 
packed droplets were transferred into a 96-well PCR 
plate for thermal cycling amplification. The protocol was 
standardized for all mutations to the following conditions: 
95°C × 10 min, 94°C × 30 s and 55°C × 60 s (35 cycles), 
98°C × 10 min, and 4°C hold. The droplet reader (BioRad®) 
was used for fluorescence signal quantification. The 
concordance between MUTKRAS and p.T790MEGFR was 
assessed on pairwise cftDNA and tissue DNA of 8 patients 
who underwent re-biopsy for diagnostic purposes. DNA was 
extracted from formalin-fixed paraffin-embedded biopsies 
using the QIAmp DNA Mini Kit (Qiagen®) and analyzed 
using conventional diagnostics as reported above. As a 
positive control for MUTKRAS, the cftDNA from 30 patients 
with known MUTKRAS pancreatic cancer was used, while the 
DNA extracted from plasma of 43 healthy blood donors was 
employed as negative control for MUTKRAS and p.T790MEGFR.
Data analysis
TTP and OS were calculated following standard 
procedures and survival curves were generated by the 
SPSS statistical software (version 16).
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